So, I’ve been told that I have GIST! Life changes suddenly and profoundly when you receive a cancer diagnosis. It’s normal to experience a state of shock, but there is a practical need to [...]
Researchers have developed a test that can accurately identify over 20% of GIST patients that are unlikely to respond to currently approved treatments. In addition, it can identify which patients need a higher dose [...]
Dr. Chris Corless In August, the LRG Webcast Series presented “Mutational Analysis of GISTs: How, When and Why.” Dr. Christopher Corless of Oregon Health and Science University (OHSU) presented the hour- long webcast [...]
A new blood testing technology may lead to major changes in treatment of Gastrointestinal Stromal Tumors. In a study presented in April by Dr. George Demetri of the Dana-Farber Cancer Institute at the American Association for Cancer Research annual meeting, the blood test was shown to be more effective than traditional biopsies in identifying secondary mutations in GIST.
The issue of personalized medicine, also referred to as "precision medicine" in the article, was addressed in a newsletter article by LRG Executive Director Norman Scherzer in February. We hope to follow up with more articles on the topic soon.
Executive Director’s report focuses on better treatment options for GISTers For my Executive Director’s report, I usually highlight the many accomplishments of the Life Raft Group. Some of which include: Launching a GIST Day of [...]
A new gene panel takes mutation testing to a new level. The panel tests for mutations in 23 genes at once will help to properly classify wild-type GIST patients. Working with next generation sequencing and [...]
Mutational testing determines whether you have a mutation present in your tumor, and what genotype it is. Examples include Exon 11 or 9 (for KIT positive tumors), Platelet Driven Growth Factor Receptor Alpha (PDGFRA), or [...]
Recently, the Life Raft Group began work on a survey project sponsored by Novartis Pharmaceuticals designed to assess knowledge and practices among patients and physicians regarding mutational analysis and plasma level testing.
As of May 1, 2011, the LRG patient registry only received 377 reports of mutations out of 1,327 patients, which only represents 28 percent of the entire registry. Part of this may be related to the fact that mutational testing is not common practice at diagnosis.